Drug Profile

B-cell based antigen vaccine - Femtobiomed

Latest Information Update: 28 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Femtobiomed
Class Antigens; Cancer vaccines; Immunotherapies
Mechanism of Action B cell stimulants; Immunologic cytotoxicity; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Nov 2023 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
21 Oct 2019 B-cell based antigen vaccine - Femtobiomed is available for licensing as of 21 Oct 2019. https://www.femtobiomed.com/index.html
21 Oct 2019 Femtobiomed files for patent protection for Cell Shot delivery technology in South Korea (Femtobiomed company website, October 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com